$954 Million is the total value of Camber Capital Management LP's 34 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DGX | QUEST DIAGNOSTICS INC | $49,432,000 | +1.9% | 800,000 | 0.0% | 5.18% | +3.9% | |
| MASI | MASIMO CORP | $46,620,000 | +25.7% | 1,750,000 | 0.0% | 4.89% | +28.1% | |
| CAH | CARDINAL HEALTH INC | $39,112,000 | +10.5% | 750,000 | 0.0% | 4.10% | +12.6% | |
| HUM | HUMANA INC | $37,332,000 | +10.6% | 400,000 | 0.0% | 3.91% | +12.7% | |
| CNMD | CONMED CORP | $33,990,000 | +8.8% | 1,000,000 | 0.0% | 3.56% | +10.9% | |
| GIVN | GIVEN IMAGING | $28,845,000 | +37.3% | 1,500,000 | 0.0% | 3.02% | +39.9% | |
| ANGO | ANGIODYNAMICS INC | $17,523,000 | +17.0% | 1,327,500 | 0.0% | 1.84% | +19.3% | |
| DSCI | DERMA SCIENCES INC | $11,761,000 | -7.3% | 950,000 | 0.0% | 1.23% | -5.4% | |
| GNMK | GENMARK DIAGNOSTICS INC | $11,542,000 | +17.5% | 950,000 | 0.0% | 1.21% | +19.8% | |
| MNTA | MOMENTA PHARMACEUTICALS INC | $11,512,000 | -4.4% | 800,000 | 0.0% | 1.21% | -2.6% | |
| MGLN | MAGELLAN HEALTH SVCS INC | $10,493,000 | +6.9% | 175,000 | 0.0% | 1.10% | +9.0% | |
| CCRN | CROSS CTRY HEALTHCARE INC | $9,332,000 | +17.4% | 1,540,000 | 0.0% | 0.98% | +19.7% | |
| BLUE | BLUEBIRD BIO INC | $4,044,000 | +8.0% | 150,000 | 0.0% | 0.42% | +10.1% | |
| ANTH | ANTHERA PHARMACEUTICALS INCwarrant | $0 | – | 400,000 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.